Diagnostic Biomarkers Industry - Regional Synopsis
North America industry is likely to account for largest revenue share by 2037, impelled by efficient healthcare sector, supported by high government investment.The market in North America industry is set to hold largest revenue share by 2037, impelled by efficient healthcare sector, supported by high government investment. Moreover, technological advancement, increasing funding for R&D activities, and development of novel diagnostic tools, is estimated to boost the market growth. The market in the Asia Pacific region is estimated to witness highest CAGR over the forecast period on account of increasing prevalence of cancer and other chronic diseases, along with the developing healthcare sector and economic development in the region.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of diagnostic biomarkers is assessed at USD 68.64 billion.
Diagnostic Biomarkers Market size was over USD 62.43 billion in 2024 and is projected to reach USD 263.08 billion by 2037, witnessing around 11.7% CAGR during the forecast period i.e., between 2025-2037.
North America industry is likely to account for largest revenue share by 2037, impelled by efficient healthcare sector, supported by high government investment.
The major players in the market are PerkinElmer Inc., Biomarker Technologies, Inc., Almac Group Limited, Myriad Genetics, Inc., F. Hoffmann-La Roche Ltd, Epigenomics AG, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., QIAGEN GmbH and others.
